Merck KGaA forecast lackluster earnings in guidance that reflects generic competition for its multiple sclerosis blockbuster drug Mavenclad, but not the potential benefits from the US launch of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results